Draft guidance consultation You can now review and comment on this draft guideline. The consultation closes on Tuesday 08 July 2025 at 5pm. In line with NICE’s commitment to incorporate technology ...

The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

NICE news for life sciences Every 2 months Our latest news and updates for those working within the life sciences sector. Subscribe for information on: our work to improve patient access to innovative ...

01 July 2025 via Zoom Draft Agenda The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to ...

Home NICE Guidance Conditions and diseases Musculoskeletal conditions Arthritis Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [ID6297] ...

Home NICE Guidance Conditions and diseases Diabetes and other endocrinal, nutritional and metabolic conditions Obesity Setmelanotide for treating acquired hypothalamic obesity in people 4 years and ...

In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented a digital innovation to support children's mental health. In recent years, ...

Marstacimab (Hympavzi, Pfizer) is indicated for 'routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: severe haemophilia A (congenital factor ...

Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any ...

Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.